DDR1 is implicated in fibrotic disorders and DDR1 inhibition has been associated with decreased vascular fibrosis in mouse models of AD (Hebron et al, 2013a, 2014; Fowler et al, 2020; Stevenson et al, 2023), whereas CSF1R is a cell-surface receptor expressed on myeloid cells, including microglia, and has been targeted by therapies aimed at reducing neuroinflammation in neurodegenerative diseases including AD (Olmos-Alonso et al, 2016). Here, CSF1R is linked to Alzheimer disease.